NASDAQ:GTXI

GTX (GTXI) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$8.75
$8.75
50-Day Range
$1.20
$7.20
52-Week Range
$0.74
$25.60
Volume
337 shs
Average Volume
390,540 shs
Market Capitalization
$210.32 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
GTXI stock logo

About GTX Stock (NASDAQ:GTXI)

GTx, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of medicines for the treatment of stress urinary incontinence (SUI) and prostate cancer. It develops selective androgen receptor modulators (SARMs) for the treatment of breast cancer, SUI, and Duchenne muscular dystrophy; and selective androgen receptor degraders to treat progressive castration-resistant prostate cancer. The company's SARM product candidate is the enobosarm GTx-024, a Phase II proof-of-concept clinical trial for patients with androgen receptor (AR) positive triple-negative breast cancer; and estrogen receptor positive and AR positive advanced breast cancer, as well as postmenopausal women with SUI. GTx, Inc. was founded in 1997 and is headquartered in Memphis, Tennessee.

GTXI Stock News Headlines

The Gold Grab of the Century
When central banks buy gold… The rich buy right along with them. And central banks are buying at breakneck pace. Last year… 1,037 tons. Just 45 tons less than the record set two years ago.
64 Gifts for New Dads That He Will Love
The Gold Grab of the Century
When central banks buy gold… The rich buy right along with them. And central banks are buying at breakneck pace. Last year… 1,037 tons. Just 45 tons less than the record set two years ago.
Volkswagen reveals hot new ID Buzz GTX
See More Headlines
Receive GTXI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for GTX and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/15/2018
Today
5/06/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:GTXI
CUSIP
40052B10
Fax
N/A
Employees
21
Year Founded
N/A

Profitability

Net Income
$-38,420,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$1.09 per share

Miscellaneous

Free Float
N/A
Market Cap
$210.32 million
Optionable
Not Optionable
Beta
2.22
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

  • Dr. Robert James Wills B.S. (Age 65)
    M.S., Ph.D., Exec. Chairman
  • Mr. Marc S. Hanover (Age 56)
    Co-Founder, CEO & Director
  • Mr. Henry P. Doggrell (Age 70)
    VP, Chief Legal Officer & Sec.
  • Mr. Jason T. Shackelford (Age 44)
    VP of Fin. & Accounting, Principal Financial & Accounting Officer and Corp. Controller
  • Dr. Diane C. Young (Age 62)
    VP & Chief Medical Officer

GTXI Stock Analysis - Frequently Asked Questions

How were GTX's earnings last quarter?

GTx, Inc. (NASDAQ:GTXI) released its earnings results on Thursday, November, 15th. The biopharmaceutical company reported ($0.39) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.30) by $0.09.

What other stocks do shareholders of GTX own?
This page (NASDAQ:GTXI) was last updated on 5/6/2024 by MarketBeat.com Staff

From Our Partners